Thera-SAbDab

ASCRINVACUMAB

>   Structural Summary
TherapeuticAscrinvacumab
TargetACVRL1
Heavy ChainQVQLQESGPGLVKPSQTLSLTCTVSGGSISSGEYYWNWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARESVAGFDYWGQGTLVTVSS
Light ChainEIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGTSSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPITFGQGTRLEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG2
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2015
INN Year Recommended2016
Companies InvolvedDuke University Medical Center, Fondazione IRCCS Istituto Nazionale dei Tumori, Pfizer, Suzhou Kintor Pharmaceuticals
Conditions Approvedna
Conditions ActiveAge-related macular degeneration, Cancer, Liver Cancer
Conditions DiscontinuedColorectal cancer, Liver cancer, Solid tumours, Urogenital cancer
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]